Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity. - Thompson-Peach CAL; Thomas D; Dottore M; Lim K; Stomski F; Panagopoulos RA; Foßelteder J; Reinisch A; Chandrakanthan V; Jenkner S; Bland L; Paton S; et al. (Blood, 2026)